Variant estrogen receptor-α messenger RNA expression in hormone-independent human breast cancer cells

A S Coutts, E Leygue and L C Murphy

Department of Biochemistry and Molecular Biology, University of Manitoba, 770 Bannatyne Avenue, Winnipeg, Manitoba, Canada R3E 0W3

(Requests for offprints should be addressed to A S Coutts; Email: lcmurph@cc.umanitoba.ca)

ABSTRACT

T5-PRF cells are insensitive to the growth-stimulatory effects of estrogen while still retaining expression of estrogen receptor-α (ER-α). In the apparent absence of ligand, T5-PRF cells have a 3.6 ± 0.5 (s.e.m.)-fold increased basal ER-α activity and elevated basal progesterone receptor levels compared with the parent, estrogen-sensitive, T5 cells. Long-range ER-α reverse transcription-PCR was performed to characterize variant ER-α mRNA expression in the two cell lines. An increased relative expression of an exon 3/4-deleted ER-α mRNA variant was found in T5-PRF. Recombinant expression of this ER-α variant resulted in significantly increased estrogen responsiveness, as well as a trend to increased basal ligand-independent activity when expressed with wild-type ER-α in ER-negative cell lines, as well as significantly increasing both ligand-independent and estrogen-induced ER-α transcriptional activity when expressed in parental T5 cells. These results suggest a role for altered variant ER-α in ligand-independent activation of ER-α which may contribute to hormone independence in breast tumors.

Journal of Molecular Endocrinology (1999) 23, 325–336

INTRODUCTION

Breast cancer is a hormonally responsive cancer and hormones, including estrogen, are required for breast cancer growth (Dickson 1991). Estrogens promote the growth of human breast cancer, and as such, most endocrine therapies are aimed at blocking the growth-promoting effects of estrogen (e.g. antiestrogen such as tamoxifen). Breast cancers are classified according to their requirement for proliferation as being either hormone dependent or hormone independent, based ultimately on the response to endocrine therapy of metastatic disease (Nandi et al. 1995). The level of estrogen receptor-α (ER-α) in human breast cancer is used as a marker not only of potential therapeutic response to endocrine therapy, but as a marker of prognosis and survival (Merkel & Osborne 1989).

The evolution of breast cancer into an estrogen-independent growth phenotype is thought to be an important step in the progression of breast cancer to hormone independence and endocrine therapy resistance (Clarke et al. 1990, Leonessa et al. 1992). Understanding the factors that contribute to the development of a hormone-independent phenotype is of major importance in terms of breast cancer therapeutics. Resistance to endocrine therapies may be due to a number of factors. In some cases, hormone independence and resistance can occur due to loss of ER expression, but most tumors that have developed resistance to endocrine therapy remain receptor positive (Horwitz 1993).

Several breast cancer cell lines in culture also require estrogen for growth, and long-term culture in estrogen-depleted conditions can result in cells becoming apparently independent of the requirement for estrogen for growth. Indeed, the development of estrogen-independent growth in human breast cancer is thought to be one of the initial steps in the progression to hormone independence and resistance to endocrine therapies (Leonessa et al. 1992). However, the mechanisms responsible for the development of estrogen independence in the presence of continued expression of ER-α are poorly understood. In order to address this we have developed a breast cancer cell model of apparent estrogen independence (Coutts et al. 1996). T5 human breast cancer cells are ER-α positive and...
estrogen treatment in culture results in increased proliferation of these cells. An estrogen-nonresponsive cell line, T5-PRF, was developed from T5 cells by chronically depleting the cells of estrogen in long-term culture. These cells are insensitive to the growth-stimulatory effects of estrogen seen in the parent cell line while still retaining expression of the ER-α (Coutts et al. 1996). However, these cells remain sensitive to the growth inhibitory effects of 4-hydroxy-tamoxifen (OT) and ICI 164,384 (ICI), although they have reduced sensitivity to ICI compared with the parent T5 cells (Coutts et al. 1996).

We have investigated the ligand-dependent and -independent activity of the endogenous ER-α as well as the pattern and potential function of ER-α variant expression in T5 and T5-PRF human breast cancer cells.

MATERIALS AND METHODS

Materials

($^{32}$P)dCTP and ($^{35}$S)ATP were purchased from ICN (St-Laurent, Quebec, Canada). Dulbecco’s Minimal Essential Medium (DMEM) powder and fetal bovine serum were purchased from GIBCO/BRL (Burlington, Ontario, Canada). Horse serum and epidermal growth factor (EGF) were purchased from ICN (St-Laurent, Quebec, Canada). Dulbecco’s Minimal Essential Medium (DMEM) powder and fetal bovine serum were purchased from GIBCO/BRL (Burlington, Ontario, Canada). Horse serum and epidermal growth factor (EGF) were purchased from ICN (St-Laurent, Quebec, Canada). Dulbecco’s Minimal Essential Medium (DMEM) powder and fetal bovine serum were purchased from GIBCO/BRL (Burlington, Ontario, Canada). Horse serum and epidermal growth factor (EGF) were purchased from ICN (St-Laurent, Quebec, Canada). Dulbecco’s Minimal Essential Medium (DMEM) powder and fetal bovine serum were purchased from GIBCO/BRL (Burlington, Ontario, Canada). Horse serum and epidermal growth factor (EGF) were purchased from ICN (St-Laurent, Quebec, Canada). Dulbecco’s Minimal Essential Medium (DMEM) powder and fetal bovine serum were purchased from GIBCO/BRL (Burlington, Ontario, Canada). Horse serum and epidermal growth factor (EGF) were purchased from ICN (St-Laurent, Quebec, Canada). Dulbecco’s Minimal Essential Medium (DMEM) powder and fetal bovine serum were purchased from GIBCO/BRL (Burlington, Ontario, Canada). Horse serum and epidermal growth factor (EGF) were purchased from ICN (St-Laurent, Quebec, Canada). Dulbecco’s Minimal Essential Medium (DMEM) powder and fetal bovine serum were purchased from GIBCO/BRL (Burlington, Ontario, Canada). Horse serum and epidermal growth factor (EGF) were purchased from ICN (St-Laurent, Quebec, Canada). Dulbecco’s Minimal Essential Medium (DMEM) powder and fetal bovine serum were purchased from GIBCO/BRL (Burlington, Ontario, Canada). Horse serum and epidermal growth factor (EGF) were purchased from ICN (St-Laurent, Quebec, Canada). Dulbecco’s Minimal Essential Medium (DMEM) powder and fetal bovine serum were purchased from GIBCO/BRL (Burlington, Ontario, Canada). Horse serum and epidermal growth factor (EGF) were purchased from ICN (St-Laurent, Quebec, Canada). Dulbecco’s Minimal Essential Medium (DMEM) powder and fetal bovine serum were purchased from GIBCO/BRL (Burlington, Ontario, Canada). Horse serum and epidermal growth factor (EGF) were purchased from ICN (St-Laurent, Quebec, Canada). Dulbecco’s Minimal Essential Medium (DMEM) powder and fetal bovine serum were purchased from GIBCO/BRL (Burlington, Ontario, Canada). Horse serum and epidermal growth factor (EGF) were purchased from ICN (St-Laurent, Quebec, Canada). Dulbecco’s Minimal Essential Medium (DMEM) powder and fetal bovine serum were purchased from GIBCO/BRL (Burlington, Ontario, Canada). Horse serum and epidermal growth factor (EGF) were purchased from ICN (St-Laurent, Quebec, Canada). Dulbecco’s Minimal Essential Medium (DMEM) powder and fetal bovine serum were purchased from GIBCO/BRL (Burlington, Ontario, Canada). Horse serum and epidermal growth factor (EGF) were purchased from ICN (St-Laurent, Quebec, Canada). Dulbecco’s Minimal Essential Medium (DMEM) powder and fetal bovine serum were purchased from GIBCO/BRL (Burlington, Ontario, Canada). Horse serum and epidermal growth factor (EGF) were purchased from ICN (St-Laurent, Quebec, Canada). Dulbecco’s Minimal Essential Medium (DMEM) powder and fetal bovine serum were purchased from GIBCO/BRL (Burlington, Ontario, Canada). Horse serum and epidermal growth factor (EGF) were purchased from ICN (St-Laurent, Quebec, Canada). Dulbecco’s Minimal Essential Medium (DMEM) powder and fetal bovine serum were purchased from GIBCO/BRL (Burlington, Ontario, Canada). Horse serum and epidermal growth factor (EGF) were purchased from ICN (St-Laurent, Quebec, Canada). Dulbecco’s Minimal Essential Medium (DMEM) powder and fetal bovine serum were purchased from GIBCO/BRL (Burlington, Ontario, Canada). Horse serum and epidermal growth factor (EGF) were purchased from ICN (St-Laurent, Quebec, Canada). Dulbecco’s Minimal Essential Medium (DMEM) powder and fetal bovine serum were purchased from GIBCO/BRL (Burlington, Ontario, Canada). Horse serum and epidermal growth factor (EGF) were purchased from ICN (St-Laurent, Quebec, Canada). Dulbecco’s Minimal Essential Medium (DMEM) powder and fetal bovine serum were purchased from GIBCO/BRL (Burlington, Ontario, Canada). Horse serum and epidermal growth factor (EGF) were purchased from ICN (St-Laurent, Quebec, Canada). Dulbecco’s Minimal Essential Medium (DMEM) powder and fetal bovine serum were purchased from GIBCO/BRL (Burlington, Ontario, Canada). Horse serum and epidermal growth factor (EGF) were purchased from ICN (St-Laurent, Quebec, Canada). Dulbecco’s Minimal Essential Medium (DMEM) powder and fetal bovine serum were purchased from GIBCO/BRL (Burlington, Ontario, Canada). Horse serum and epidermal growth factor (EGF) were purchased from ICN (St-Laurent, Quebec, Canada). Dulbecco’s Minimal Essential Medium (DMEM) powder and fetal bovine serum were purchased from GIBCO/BRL (Burlington, Ontario, Canada). Horse serum and epidermal growth factor (EGF) were purchased from ICN (St-Laura...
d’Urfé, Québec, Canada) and assay of β-galactosidase activity (Rosenthal 1987) was used to correct volumes of cell extracts used for CAT assay. Therefore all results are expressed as percent CAT activity or fold CAT activity after correction for transfection efficiency. T5 and T5-PRF cells were transfected with 5 µg estrogen response element (ERE)-thymidine kinase (tk)-CAT (Seiler-Tuyns et al. 1986), to determine ER-α transcriptional activity, along with 5 µg pCH110. In the experiments where activity of exon 3/4-deleted ER-α (d3/4) was examined in T5 cells, transfections were performed using 5 µg ERE-tk-CAT, 5 µg pCH110 plus or minus d3/4 expression vector (0–1 pmol) or vector DNA alone. MDA-MB-231 and MCF10A1 cells were transfected with 5 µg estrogen response element (ERE)-tk-CAT, 5 µg pCH110, or vector DNA alone. MDA-MB-231 and MCF10A1 cells were transfected with 5 µg estrogen response element (ERE)-thymidine kinase (tk)-CAT (Seiler-Tuyns et al. 1986), to determine ER-α transcriptional activity, along with 5 µg pCH110. In the experiments where activity of exon 3/4-deleted ER-α (d3/4) was examined in T5 cells, transfections were performed using 5 µg ERE-tk-CAT, 5 µg pCH110 plus or minus d3/4 expression vector (0–1 pmol) or vector DNA alone.

In vitro transcription and translation

In vitro transcription/translation reactions were performed using a coupled transcription/translation system (TnT coupled Reticulocyte Lysate System, Promega, Madison, WI, USA). Reactions were performed according to the manufacturer’s instructions.

Construction of variant ER-α expression vector

The RT-PCR product corresponding to the d3/4 cDNA was cloned into the TA cloning vector (Invitrogen TA cloning kit, Carlsbad, CA, USA). StuI digestion of this plasmid released an exon 3/4-deleted fragment which was used to replace the corresponding region of wild-type ER-α from pOR8 (Tora et al. 1989a) containing a glycine to valine point mutation at amino acid 400. StuI sites are in exon 2 and 7 of wild-type ER-α and the subcloned d3/4 PCR fragment resulted in a correction to the wild-type sequence of glycine at amino acid 400 (in exon 5 in pOR8). The full-length EcoRI ER-α fragment from HEGO was then excised and replaced with the corresponding fragment from pOR8 containing the d3/4 cDNA. The identity of the expression plasmid containing the d3/4 was confirmed by restriction enzyme digest and sequence analysis.

Long-range ER-α reverse transcriptase (RT)-PCR

Total RNA was extracted (Trizol reagent, GIBCO/BRL, Grand Island, New York, NY, USA) and reverse transcribed as described previously (Leygue et al. 1996c). The primer pair used consisted of 1/8U primer (5′-TGCCCTACTACCTGGAGAAGCG-3′, sense; located in WT-ER-α exon 1; nucleotides 615–637) and 1/8L primer (5′-GCC TCCCCGTTGATGTAAA-3′, antisense; located in WT-ER-α exon 8; nucleotides 1995–1978). Nucleotide positions given correspond to published sequences of the human ER-α cDNA (Green et al. 1986). PCR amplifications were performed as previously described (Leygue et al. 1996a). PCR products were separated on 3% polyacrylamide gels containing 7 M urea, gels dried and labeled products visualized by autoradiography. PCR products were subcloned and sequenced as previously described (Leygue et al. 1996c).

Western blotting and immune detection

Whole-cell extracts (dissolved in 8 M urea) were analyzed using 10% SDS-PAGE with a 4% stacking gel at 200 V for 45 min at room temperature according to the Laemmli method (Laemmli 1970). Gels were transferred to nitrocellulose using CAPS transfer buffer (10 mM 3-[cyclohexylamino]-1-propanesulfonic acid (CAPS), pH 11, 20% methanol) and transferred for 1 h at 120 V at 4°C. Blots were blocked for 1 h at room temperature in 5% skimmed milk/Tris-buffered saline containing 0.5% Tween-20. Blots were incubated with either ER-α-specific primary antibody, H226 (a generous gift from Dr G Greene, University of Chicago, IL, USA), which recognizes an epitope in exon 1/exon 2 region of the wild-type ER-α, or the ER-α-specific antibody, AER 308 (Neomarkers, Fremont, CA, USA), which recognizes an epitope in exon 4 of the wild-type ER-α, overnight at 4°C in 1% skimmed milk/Tris-buffered saline containing 0.5% Tween-20. Blots were then incubated with the appropriate peroxidase-conjugated secondary antibody for 1 h at room temperature in 1% skimmed milk/Tris-buffered saline containing 0.5% Tween-20. Detection was carried out using an enhanced chemiluminescence detection system according to the manufacturer’s instructions (Amersham International, Amersham, Bucks, UK).

Statistical analysis

Statistical analyses of ER-α transcriptional activity and PR levels were performed using paired Student’s t-test. Statistical analysis on the effects of
d3/4 on ERE-tk-CAT activity in MDA-MB-231 and MCF10A1 cells was done by ANOVA (two-tailed). Statistical analysis on the effects of d3/4 on ERE-tk-CAT activity in T5 cells was done by ANOVA (two-tailed) after log transformation of the data. Statistical analyses were performed with the help of M Cheang, University of Manitoba, Biostatistical Consulting Unit.

RESULTS

Apparent ligand-independent (basal) activity of ER-α is increased in T5-PRF cells

Previously, we have shown that T5-PRF cells (derived by long-term passage of parental T5 cells in estrogen-depleted medium) are no longer growth responsive to estrogen in culture, but still retain expression of ER-α (Coutts et al. 1996). To investigate further the mechanism(s) responsible for estrogen nonresponsiveness in these cells, ER-α transcriptional activity was examined by transient transfection assays using an estrogen-responsive reporter gene. Figure 1A represents the fold difference in CAT activity between T5 and T5-PRF cells. As expected, estrogen treatment increases CAT activity in T5 and to a lesser extent in T5-PRF cells, while the antiestrogen ICI inhibits the estrogen-induced transcriptional activity of the ER-α in both cell lines. In the absence of added estrogen there is a low basal ER-α activity in parental T5 cells; however, in the estrogen-nonresponsive T5-PRF cells, the basal ER-α activity was 3·6 ± 0·5-fold (mean ± s.e.m., n=7) higher than that seen in T5 cells (P>0·05). Consistent with the increased basal CAT activity in T5-PRF cells being mediated by ER-α, treating cells under basal conditions with ICI alone almost completely abolished the basal transcriptional activity measured (Fig. 1B).

PR levels are elevated in T5-PRF cells

PR expression is a marker of ER-α activity (Horwitz & McGuire 1978), therefore we examined PR levels to determine if the increase in basal ER-α activity in T5-PRF cells was reflected in an endogenous estrogen-responsive gene. Under basal (i.e. no added estrogen) conditions the T5-PRF cells have significantly higher PR levels (~3-fold) than the parent T5 cells passed twice in estrogen-depleted medium (PRF/DMEM as defined in Materials and Methods) before receptor assays (464 ± 20 fmol/10⁶ cells vs 148 ± 40 fmol/10⁶ cells, mean ± s.e.m., n=3, see Fig. 2). Previously, we had shown that T5-PRF cells retained expression of ER-α which was approximately 50% of the levels seen in the parent T5 cells, as determined by a ligand-binding assay (Coutts et al. 1996). Since we observed increased basal activity from both an estrogen-responsive reporter gene and an endogenous estrogen-responsive gene (PR) in T5-PRF cells despite a decreased level of endogenous ligand-binding ER, we reasoned that the intrinsic activity of the wild-type ER in these cells was increased or some
ER-like activity existed that was not detected by ligand-binding experiments.

**Expression of a variant ER-α mRNA deleted in exons 3 and 4 is increased in T5-PRF cells**

Alterations in the structure or presence of variant forms of the ER-α with ligand-independent activity could be one mechanism for our observed results. Long-range ER-α RT-PCR analysis (Leygue et al. 1996a) was performed on RNA isolated from T5 and T5-PRF cells to examine the pattern of deleted variant ER-α mRNA expression. RT-PCR analysis was performed, using a primer pair specific for exons 1 and 8 of the wild-type human ER-α sequence, allowing detection of any variant ER-α mRNA species containing both exons 1 and 8 of wild-type ER-α sequence. Figure 3 shows the PCR products obtained and the presence of a 928 bp band whose relative expression is markedly increased in T5-PRF estrogen-independent cells. To confirm the identity of this variant, the cDNA corresponding to the 928 bp band was subcloned.

---

**Figure 2.** PR levels. PR levels were determined by whole-cell binding as described in Materials and Methods. PR levels are expressed as fmol PR/10^6 cells and results represent mean ± s.e.m., n=3. **P<0.01, Student’s t-test.**

**Figure 3.** Identification of d3/4 mRNA. (A) Long-range ER-α RT-PCR. Total RNA was extracted from T5 and T5-PRF cells, reverse transcribed and PCR amplified using 1/8U and 1/8L primers. Labeled PCR products were separated on 3.5% acrylamide–urea gels and visualized using autoradiography. WT-ER=wild type ER-α, D7-ER=exon 7-deleted ER-α, D4-ER=exon 4-deleted ER-α and D3/4-ER=exon 3 and 4-deleted ER-α (d3/4), based on size compared with labeled markers (not shown). (B) Sequence of d3/4 cDNA. The 928 bp PCR product was excised from a gel and subcloned (in triplicate) and three colonies from each independent subcloning were sequenced to confirm the identity of d3/4 cDNA.
and sequenced. The nucleotide sequence of the cDNA was found to represent a variant ER-α mRNA containing a deletion of both exons 3 and 4. This d3/4 is in frame and is predicted to encode a protein of 443 amino acid residues with a predicted molecular mass of ~49 kDa. This putative ER-α-like protein would be missing the second zinc finger of the ER-α DNA-binding domain (DBD), the hinge region and part of the ligand-binding domain.

The exon 3/4-deleted ER-α-like protein increases basal and estrogen-regulated wild-type ER-α transcriptional activity

To address the potential function of this variant ER-α mRNA eukaryotic expression vectors containing d3/4 cDNA were constructed and shown to express a protein of the appropriate size that was recognized by the ER-α antibody H226 that recognizes an epitope encoded in exon 1/2 (A/B region) of wild-type ER-α (data not shown). Using an antibody that recognizes an epitope encoded in exon 4 of the wild-type ER-α the band corresponding to the d3/4 protein is not seen, while wild-type ER-α is still detected (data not shown). Ligand-binding analysis of the in vitro-translated d3/4 protein showed little or no ability to specifically bind radiolabeled E2 or OT (data not shown). This protein is missing the second zinc finger of the DBD and as such would not be expected to bind to DNA. We found that under conditions in which in vitro-transcribed/translated wild-type ER-α could bind to an oligonucleotide containing the vitellogenin B1 ERE, d3/4 did not demonstrate any specific DNA binding in gel mobility shift assays (data not shown).

To examine the transcriptional activity of the d3/4 variant, transient transfections using ER-negative cell lines were carried out. Under conditions in which transiently transfected wild-type ER-α was transcriptionally active and able to induce CAT activity in a ligand-dependent fashion, the d3/4 did not demonstrate any transcriptional activity on its own (data not shown). This is unlikely to be due to low levels of expression of this transgene, since after transfection of 5 µg d3/4 vector into MCF10A1 cells we were able to detect a protein corresponding in size to the expected d3/4 protein (Fig. 4). To determine if d3/4 and wild-type ER-α could interact to influence transcription, cotransfections of wild-type ER-α and d3/4 into MDA-MB-231 and MCF10A1 ER-negative breast epithelial cell lines were carried out (Fig. 5A and B). HEGO transfected alone showed the expected estrogen-dependent activity (Fig. 5A and B) while d3/4 alone had no transcriptional activity. However, when increasing amounts of d3/4 were cotransfected with a constant amount of HEGO into MDA-MB-231 cells, d3/4 significantly increased estrogen-dependent activity of wild-type ER-α (ANOVA, P<0.0001). Furthermore, although it did not reach statistical significance there was a trend of increased d3/4 to increase the basal level of activity of the wild-type ER-α. This pattern of activity was also seen when similar experiments were carried out in MCF10A1 cells. A significant increase in the estrogen-dependent activity was seen (ANOVA, P<0.05), with a trend towards increased basal activity.

We next examined the effects of introducing the d3/4 into the parental T5 cells. Transient transfection of d3/4 into T5 cells was carried out and ER-α transcriptional activity measured. Figure 6 shows

![Western blot showing expression of ER-α variants](image-url)
the results, and demonstrates that increasing amounts of d3/4 transiently transfected into T5 cells were associated with a significant increase in CAT activity in both the presence and absence of added estrogen (ANOVA, $P<0.05$ and $P<0.0001$ respectively) despite the fact that this variant ER-$\alpha$ does not bind appreciably to ligand in vitro nor has transcriptional activity of its own at this concentration.

**DISCUSSION**

Numerous studies have identified variant ER-$\alpha$ mRNAs in both normal and neoplastic breast tissue and cell lines (Garcia et al. 1988, Murphy & Dotzlaw 1989b, Fuqua et al. 1992, McGuire et al.)

However, the pathophysiological significance of ER-α variant expression is unclear. Altered expression of some ER-α variant mRNAs was found associated with both breast tumorigenesis and breast cancer progression (Fuqua et al. 1992, Daffada et al. 1995, Murphy et al. 1995, Leygue et al. 1996b,c). Several studies, using transient transfection analyses, have shown that individual ER-α variant proteins can have both positive and negative effects on wild-type ER-α activity (Fuqua et al. 1991, 1992, Wang & Mikesieck 1991, Castles et al. 1993, Pink et al. 1995, 1996, Rea & Parker 1996, Desai et al. 1997). Conflicting results for some ER-α variants have been obtained (Wang & Mikesieck 1991, Fuqua et al. 1993), which may be due to cell- and promoter-specific events previously identified for various structure/function domains of the wild-type ER-α (Tora et al. 1989b, Tzukerman et al. 1994).

Similarly, overexpression of a single ER-α variant using stable transfection technology has resulted in different results in different laboratories (Fuqua & Wolf 1995, Rea & Parker 1996). Moreover, direct correlation of any single ER-α variant with clinical tamoxifen resistance or tamoxifen resistance of breast cancer cells in culture has not been forthcoming. Since most of these comparisons have been performed using individual ER-α variants and do not take into account the entire spectrum of ER-α variants relative to each other, the conclusions remain controversial. Together, the data support the hypothesis that the development of hormone independence and endocrine resistance in human breast cancer is a multifactorial process and indeed there are many examples where the development of estrogen-independent growth and antiestrogen resistance are dissociable events in breast cancer cell line models (Katzellenbogen et al. 1987, Welshons & Jordan 1987, Van der Berg et al. 1990, Brunner et al. 1993).

Similar to these and other studies, we have found that the development of estrogen-independent growth in a breast cancer cell line model, through long-term growth in estrogen-depleted medium, was not associated with antiestrogen resistance. Although the estrogen-nonresponsive T5-PRF cells have a reduced sensitivity to the pure antiestrogen ICI, their growth response to OT is identical to that of parental T5 cells (Coutts et al. 1996).

However, when we investigated the relative pattern of expression of ER-α-deleted variant mRNA in T5-PRF compared with parental T5 cells, there was a significant difference in the relative expression of a previously described exon 3/4-deleted ER-α variant mRNA (reviewed in Murphy et al. 1997). Although the question of whether this ER-α variant is a cause of estrogen independence or merely an effect of the selection process for estrogen independence requires further study, our data using transient transfection analyses tend to support a possible functional role for the putative 3/4-deleted ER-α protein encoded by the variant mRNA in the phenotype observed in T5-PRF human breast cancer cells.

In this study we have shown that T5-PRF cells have significantly increased ligand-independent (basal) ER-α activity (reflected in both ERE-tk-CAT activity and endogenous PR levels). The recombinant d3/4 variant ER-α was able to confer significantly increased ligand-independent (basal) and estrogen-responsive transcriptional activity when expressed in parental T5 cells and showed a trend towards increased basal transcriptional activity when coexpressed with wild-type ER-α in ER-α-negative human breast cell lines.

While the demonstrated effects of d3/4 on HEGO transcriptional activity in ER-α-negative cell lines suggest a putative functional role for this variant ER-α, this effect required equal or higher levels of d3/4 than HEGO. Although our data provide ‘proof of principle’ that the d3/4 variant can modulate the transcriptional activity of the wild-type ER-α the relevance of the expression levels of each protein achieved in the reconstituted transient expression system to the endogenous levels of ER-α and d3/4 variant expression in T5-PRF is unclear. Furthermore, differences in the background of transcriptional coactivators and corepressors between naturally ER-α positive and negative cell lines (for example Tzukerman et al. 1994), as well as the presence of other naturally occurring ER-α variants in naturally ER-α positive cell lines are all likely to impact on the final outcome of ER-mediated transcriptional activity and underlie the differences seen between the transiently manipulated cells and the naturally occurring T5-PRF phenotype. Moreover, expression of ER-β and/or its variants may influence estrogen action (Giguere et al. 1998). Both T5 and T5-PRF cells express low levels of ER-β mRNA determined by RT-PCR analysis (A S Coutts, H Dotzlau, E Leygue & L C Murphy, our unpublished data); however, the functional significance of the levels remains unknown. Nonetheless, we saw a significant effect on ER-α ligand-independent transcription in T5 cells at levels of...
cotransfected d3/4 that likely would not be higher than the endogenous ER-α in these cells, but the extrapolation of these data to the relative expression of wild-type ER-α and d3/4 variant in T5-PRF cells is presently unknown.

It is of significance that we can reproduce an effect of d3/4 variant in the parental T5 cells, which would likely contain a more representative background of ER-α accessory proteins (i.e. coactivators and/or corepressors) as well as other variant forms of ER-α, which would all contribute to the final ER-mediated biological response. As well, our data do not exclude the possibility that other alterations have occurred in T5-PRF cells which, in combination with an altered ER-α variant, may contribute to the estrogen-independent phenotype of T5-PRF cells (Coutts & Murphy 1998).

It has previously been shown that breast cancer cells can adapt to low levels of estrogen by enhancing their sensitivity to estrogen (Masamura et al. 1995). Estrogen deprivation of MCF-7 human breast cancer cells resulted in estrogen hypersensitivity and maximal growth was achieved with an estrogen concentration 4–5 orders of magnitude lower than wild-type cells. These researchers also found that the concentration of ICI needed to inhibit growth of these cells was ~6 orders of magnitude lower than wild-type cells, supporting the hypothesis in this model that increased sensitivity to ER ligands had occurred. While supersensitivity to estrogen in T5-PRF cells cannot be entirely ruled out, we have previously shown that in contrast to the data of Masamura et al. (1995), T5-PRF cells are less sensitive to growth inhibition by ICI, suggesting that in this model other mechanisms are likely involved.

Our data do not address the mechanism by which d3/4 enhances ER transcriptional activity, but several possibilities exist. The ER-α contains at least two separate regions that are required for optimal transcriptional activation (Tora et al. 1989b, Tzukerman et al. 1990). The N-terminal region contains promoter and cell-type-specific ligand-independent transcriptional activity (AF1) and the second, AF2, is located in the ligand-binding C-terminus of the receptor. d3/4 containing an intact AF2 or AF1 domain could interfere with, or sequester, an ER-α repressor protein resulting in increased ER-α transcriptional activity in the absence of ligand (Lee et al. 1996). This variant may also retain the ability to interact with other ER-α regulatory proteins such as coactivators or components of the basal transcription machinery.

ER-α also contains two domains involved in dimerization (Kumar & Chambon 1988, Schwabe et al. 1993). A weak dimerization interface is present in the DBD and a strong interface is located in the C-terminal ligand-binding domain (White et al. 1991). d3/4 containing an intact C-terminal dimerization domain may form heterodimers with wild-type ER-α that have altered transcriptional regulatory properties through differing protein–protein interactions.

The crystal structure of the ER-α hormone-binding domain has recently been elucidated (Brzozowski et al. 1997). Based on this structure, the d3/4 protein would contain many of the regions essential for transactivation, including the predominant helix 12 (encompassing amino acids 539–547). However, since d3/4 alone has no transcriptional activity (at least on a classical ERE-regulated promoter) the structure must be sufficiently altered to prevent activity, or AF2 can only be activated in a ligand-dependent manner but d3/4 cannot bind ligand. Helix 12 in AF2 is believed to be the main region involved in coactivator recruitment and it may be possible that d3/4, following heterodimerization with ER-α, enhances recruitment of coactivators to the basal transcription complex and this enhances ER-α activity.

We have found that the d3/4 caused increased ligand-independent wild-type ER-α activity and also enhances the ligand-induced ER-α transcriptional activity, despite the fact that on its own this variant is not transcriptionally active on a classical ERE promoter, nor does it bind ligand in vitro to any significant degree. Studies have demonstrated that the ability of steroid hormone receptors to modulate transcription does not necessarily require that the receptors bind DNA. PRc, an N-terminally truncated PR isoform lacking the first zinc-finger of the DBD, has no transcriptional activity of its own but has been shown to enhance progesterin-induced transcriptional activity (Wei et al. 1996). The DBD of the ER-α does not appear to be necessary for raloxifene activation of the transforming growth factor (TGF)-β gene (Yang et al. 1996) and ER-α can activate transcription from AP-1 dependent promoters through a DNA-binding-independent pathway (Webb et al. 1995). Sp1 and ER-α directly interact to enhance estrogen-induced transactivation of the Sp1-dependent Hsp27 gene promoter and the DBD of the ER-α is not required (Porter et al. 1997).

Recent research has demonstrated that the ER-α can be activated in a ligand-independent fashion (Ignar-Trowbridge et al. 1993). Studies have shown that several growth factors such as EGF, TGF-α and insulin-like growth factor-I were able to activate the ER-α in the absence of ligand. The ability to activate the ER-α in the absence of estrogen could confer a growth advantage to breast
cancer cells and aid in the development of a hormone-independent phenotype. The presence of alternate forms of ER-\(\alpha\) capable of interacting with wild-type ER-\(\alpha\) to increase ligand-independent activity could also confer a potential growth advantage to breast cancer cells. A recent study has shown that constitutively active, ligand-independent ER-\(\alpha\) mutants undergo conformational changes and interactions with coactivators that mimic changes in ER-\(\alpha\) that are usually regulated by ligand (Lazennec et al. 1997). Recently, researchers have shown that thyroid hormone receptor-\(\beta2\) (TR-\(\beta2\)) is a ligand-independent activator of the gene encoding thyrotropin-releasing hormone and have mapped a region in the N-terminus of the receptor responsible for this activity (Langlois et al. 1997). These researchers suggest that the mechanism of ligand-independent activation involves direct interaction of the TR-\(\beta2\) N-terminus with either transcriptional cofactors or the basal transcription machinery itself.

An increased relative expression of variant ER-\(\alpha\) proteins containing intact AF domains, could result in increased interactions with the ER-\(\alpha\) and/or other proteins involved in ER-\(\alpha\) transcriptional activity. This could be a potential mechanism for estrogen-independent growth associated with the presence of one or more variant ER species and could explain the increased ER-\(\alpha\) activity we have seen with the d3/4.

ACKNOWLEDGEMENTS

This work was supported by the US Army Medical Research and Material Command (USAMRMC). L C M is a Medical Research Council of Canada Scientist, E L is a recipient of a USAMRMC Postdoctoral Fellowship, and A S C holds a Manitoba Health Research Council Studentship. The authors also wish to acknowledge the generous contribution of the ER antibody, H226, from Dr G Green, University of Chicago, IL, USA.

REFERENCES


Langlois M, Zanger K, Monden T, Safer J, Hollenberg A & Wondisford F 1997 A unique role of the beta 2 thyroid hormone receptor isoform in negative regulation by thyroid hormone. Mapping a novel amino terminal domain important for ligand independent activation. Journal of Biological Chemistry 272 24927–24933.

Laennec G, Petz TE, Nardulli A & Katzenellenbogen B 1997 Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes. Molecular Endocrinology 11 1375–1386.


Murphy LC & Dotzlaw H 1989b Variant estrogen receptor mRNA species detected in human breast cancer biopsy samples. Molecular Endocrinology 3 687–693.


Schwabe J, Chapman L, Finch J & Rhodes D 1993 The crystal structure of the estrogen receptor DNA binding domain bound to DNA: how receptors discriminate between their response elements. Cell 75 567–578.


REVISED MANUSCRIPT RECEIVED 16 July 1999